Compass Therapeutics
CMPX
34 hedge funds and large institutions have $106M invested in Compass Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
24% more capital invested
Capital invested by funds: $85.4M → $106M (+$20.4M)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.46% less ownership
Funds ownership: 61.58% → 61.11% (-0.46%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.62M |
| 2 |
FCOMV
Foresite Capital Opportunity Management V
Larkspur,
California
|
+$986K |
| 3 |
O
OrbiMed
New York
|
+$690K |
| 4 |
BlackRock
New York
|
+$355K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$334K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MWM
26
Mascoma Wealth Management
Hanover,
New Hampshire
| $42K | – | – | – |
|
|
FHA
27
Flagship Harbor Advisors
Boston,
Massachusetts
| $37K | +$30.4K | +14,000 | New |
|
28
UBS Group
Zurich,
Switzerland
| $19K | – | – | – |
|
|
COCM
29
Charter Oak Capital Management
Portsmouth,
New Hampshire
| $4K | – | – | – |
|
30
Citigroup
New York
| $4K | +$2.97K | +1,370 | New |
|
31
Morgan Stanley
New York
| $2K | -$57.2K | -26,364 | -98% |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$1.21K | -555 | -71% |
|
|
BRWM
33
B. Riley Wealth Management
Memphis,
Tennessee
| $40 | – | – | – |
|
|
FCM
34
Farallon Capital Management
San Francisco,
California
| – | -$798K | -582,750 | Closed |
|
|
RCM
35
RA Capital Management
Boston,
Massachusetts
| – | -$730K | -532,958 | Closed |
|
|
AI
36
Alphabet Inc
Mountain View,
California
| – | -$264K | -192,794 | Closed |
|
|
IC
37
Ikarian Capital
Dallas,
Texas
| – | -$100K | -74,171 | Closed |
|
38
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$72K | -52,842 | Closed |
|
39
Osaic Holdings
Scottsdale,
Arizona
| – | +$217 | +100 | New |
|
CMPX Hedge Fund Activity: Q2 2022 in Review
34 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2022, worth a combined $106M — up 24% from $85.4M a quarter earlier.
Fund positioning in CMPX was balanced in Q2 2022: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.62M. The largest seller was Consonance Capital Management, cutting an estimated $4.12M.
- 34 institutional investors held Compass Therapeutics (CMPX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $106M of Compass Therapeutics stock for Q2 2022, up 24% quarter-over-quarter.
- 6 funds opened new Compass Therapeutics positions in Q2 2022 and 6 closed out, a net change of 0 holders.
- The largest Compass Therapeutics buyer in Q2 2022 was Adage Capital Partners, an estimated $4.62M added.
- The largest Compass Therapeutics seller in Q2 2022 was Consonance Capital Management, an estimated $4.12M sold.
Based on aggregated 13F filings for Q2 2022.